CymaBay Therapeutics (CBAY) Given Media Impact Score of 0.05
News articles about CymaBay Therapeutics (NASDAQ:CBAY) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CymaBay Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.2726716157189 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Analysts Offer Insights on Healthcare Companies: Veracyte (NASDAQ: VCYT), CymaBay Therapeutics (NASDAQ … – Analyst Ratings (analystratings.com)
- Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning – Investorplace.com (investorplace.com)
- CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary … – GlobeNewswire (press release) (globenewswire.com)
- CymaBay Therapeutics (CBAY) Achieves EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis (streetinsider.com)
- CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis (finance.yahoo.com)
Shares of CymaBay Therapeutics (NASDAQ CBAY) opened at 6.73 on Wednesday. The stock’s 50 day moving average is $6.72 and its 200 day moving average is $5.00. The company’s market capitalization is $294.48 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $8.29.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.06). Equities analysts expect that CymaBay Therapeutics will post ($0.81) EPS for the current year.
Several equities research analysts have weighed in on CBAY shares. Leerink Swann started coverage on shares of CymaBay Therapeutics in a research note on Wednesday, August 23rd. They issued an “outperform” rating and a $12.00 price target for the company. Ifs Securities reaffirmed a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Piper Jaffray Companies set a $7.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research note on Monday, July 17th. Citigroup Inc. reaffirmed an “outperform” rating and issued a $15.00 price target (up from $8.00) on shares of CymaBay Therapeutics in a research note on Thursday, July 20th. Finally, Oppenheimer Holdings, Inc. lifted their price target on shares of CymaBay Therapeutics from $8.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday, July 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $12.28.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/13/cymabay-therapeutics-cbay-given-media-impact-score-of-0-05.html.
In other CymaBay Therapeutics news, insider Sujal Shah purchased 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was bought at an average cost of $7.34 per share, for a total transaction of $73,400.00. Following the purchase, the insider now directly owns 75,891 shares in the company, valued at $557,039.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert James Wills purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average price of $6.84 per share, with a total value of $34,200.00. Following the completion of the purchase, the director now owns 25,200 shares in the company, valued at $172,368. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 20,000 shares of company stock valued at $144,750. Corporate insiders own 15.10% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.